Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Amortizatization of Intangibles (2022 - 2025)

Historic Amortizatization of Intangibles for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Q3 2025 value amounting to $800000.0.

  • Day One Biopharmaceuticals' Amortizatization of Intangibles rose 3333.33% to $800000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.7 million, marking a year-over-year increase of 13017.52%. This contributed to the annual value of $6.4 million for FY2024, which is 3660.45% down from last year.
  • Per Day One Biopharmaceuticals' latest filing, its Amortizatization of Intangibles stood at $800000.0 for Q3 2025, which was up 3333.33% from $800000.0 recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year Amortizatization of Intangibles high stood at $5.3 million for Q2 2023, and its period low was $47000.0 during Q1 2022.
  • Moreover, its 4-year median value for Amortizatization of Intangibles was $800000.0 (2025), whereas its average is $1.5 million.
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first surged by 404094.49% in 2023, then plummeted by 9429.55% in 2024.
  • Quarter analysis of 4 years shows Day One Biopharmaceuticals' Amortizatization of Intangibles stood at $1.7 million in 2022, then fell by 8.74% to $1.6 million in 2023, then surged by 79.12% to $2.8 million in 2024, then plummeted by 71.66% to $800000.0 in 2025.
  • Its last three reported values are $800000.0 in Q3 2025, $800000.0 for Q2 2025, and $4.2 million during Q1 2025.